Research progress in prognosis of diffuse large B-cell lymphoma

VernacularTitle:弥漫大B细胞淋巴瘤预后研究进展
Author: Qian ZHAO ; Jinhua LIANG ; Wei XU
Keywords: Lymphoma; large B-cell; diffuse; Prognosis; American Society of Hematology Annual Meeting
From: Journal of Leukemia & Lymphoma 2017;26(3):129-134
CountryChina
Language:Chinese
Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma with highly heterogeneous both clinically and biologically. So the prediction for prognosis of DLBCL and identifying patients with high risk are coming into the focus of the 58th American Society of Hematology (ASH) Annual Meeting. International prognostic index (IPI) risk model is widely known as the powerful prognostic indicator for DLBCL but in rituximab-era is challenged by a variety of new prognosis systems. Biological markers and mutation and expression of genes play an important role in the pathogenesis and progression of lymphoma, and its prognostic value draw much more attention. The prognostic factors of DLBCL, specific types, such as primary breast DLBCL, intravascular large B-cell lymphoma, the presence of a DLBCL component in a follicular lymphoma and relapsed/refractory DLBCL have been paid more attention in this meeting.